TETRALOGIC PHARMACEUTICALS CORP

As of September 30, 2016, TETRALOGIC PHARMACEUTICALS CORP carries a market capitalization of 3.90M, placing it among publicly traded companies globally. Its enterprise value stands at 28.82M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of September 30, 2016, TETRALOGIC PHARMACEUTICALS CORP has 24.77M shares outstanding.

These figures are as of September 30, 2016.

As of September 30, 2016, TETRALOGIC PHARMACEUTICALS CORP maintains a current ratio of 0.48, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -99.58, indicating conservative leverage, while an interest coverage ratio of -5.35 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended September 30, 2016. Return on assets (ROA) is negative at -59.95, reflecting losses generated across the asset base.

Over the twelve months ended September 30, 2016, TETRALOGIC PHARMACEUTICALS CORP recorded an income tax benefit of -2.32M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -43.04M and -40.72M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 8, 2026, TETRALOGIC PHARMACEUTICALS CORP's stock has declined approximately 99.50% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.

These figures cover the twelve months ended September 30, 2016. EBITDA reached -36.37M, while operating income came in at -23.62M.

As of September 30, 2016, TETRALOGIC PHARMACEUTICALS CORP holds 5.89M in cash and equivalents against 30.81M in total debt, resulting in a net debt position of 24.92M. Total book value stands at -30.94M, with working capital of -6.96M providing operational flexibility.

TETRALOGIC PHARMACEUTICALS CORP produced -23.88M in operating cash flow over the twelve months ended September 30, 2016. After subtracting -666.00 in capital expenditures, free cash flow totaled -23.88M - equivalent to -0.96 per share.

These figures cover the twelve months ended September 30, 2016. Free cash flow yield is negative at -612.18: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches - -, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to TETRALOGIC PHARMACEUTICALS CORP shareholders.